Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo in Patients With HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3)
This is a double-blind, randomised parallel assignment trial with experimental and active comparator arms. Participants in the active comparator arm will receive a placebo, followed by 3.6 milligrams per kilogram (mg/kg) of intravenous (IV) trastuzumab emtansine.
Participants in the Experimental arm will receive 1200 mg IV Atezolizumab followed by 3.6 mg/kg IV trastuzumab emtansine.
All participants will receive the above treatments on Day 1, Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor.